TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2SmRO28
via IFTTT